"Melphalan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
| Descriptor ID |
D008558
|
| MeSH Number(s) |
D02.455.526.728.650.594 D12.125.072.050.685.500
|
| Concept/Terms |
Melphalan- Melphalan
- L-PAM
- Phenylalanine Mustard
- Mustard, Phenylalanine
- 4-(Bis(2-chloroethyl)amino)phenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Melphalan".
Below are MeSH descriptors whose meaning is more specific than "Melphalan".
This graph shows the total number of publications written about "Melphalan" by people in this website by year, and whether "Melphalan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 4 | 3 | 7 |
| 1996 | 0 | 4 | 4 |
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 1 | 5 | 6 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 4 | 6 |
| 2002 | 2 | 4 | 6 |
| 2003 | 2 | 3 | 5 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 4 | 5 |
| 2006 | 3 | 2 | 5 |
| 2007 | 4 | 11 | 15 |
| 2008 | 3 | 6 | 9 |
| 2009 | 6 | 4 | 10 |
| 2010 | 2 | 6 | 8 |
| 2011 | 5 | 6 | 11 |
| 2012 | 2 | 7 | 9 |
| 2013 | 2 | 3 | 5 |
| 2014 | 1 | 3 | 4 |
| 2015 | 3 | 5 | 8 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 9 | 10 |
| 2018 | 3 | 4 | 7 |
| 2019 | 1 | 6 | 7 |
| 2020 | 0 | 8 | 8 |
| 2021 | 0 | 5 | 5 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 10 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melphalan" by people in Profiles.
-
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol. 2024 02; 99(2):245-253.
-
Incidence and Risk Factors for Neutropenia After Intra-Arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol. 2023 Dec 01; 141(12):1133-1138.
-
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2024 Apr; 262(4):1321-1328.
-
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies. Blood Cancer J. 2023 11 15; 13(1):170.
-
A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Pediatr Blood Cancer. 2024 Jan; 71(1):e30718.
-
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther. 2023 Nov; 29(11):690-694.
-
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734.
-
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 07 01; 108(7):1900-1908.
-
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.
-
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.